Verastem to Present at BIO CEO and Leerink Swann Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced presentations at several upcoming investment conferences. The conference and Verastem presentation details are as follows:

  • 14th Annual BIO CEO & Investor Conference at 2:00pm ET on Monday, February 13, 2012 at the Waldorf Astoria Hotel in New York City.
  • Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012 at 8:00 am ET at the Waldorf Astoria Hotel in New York City.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.



CONTACT:

Verastem, Inc.
Lacy Roosevelt, 617-520-7052
[email protected]

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.